

# **Towards Immuno-profiling of Complex Biological Fluids in Patients Recovering from Major Surgery**

---

Submitted by Stephanus Bernardus Jansen van Vuuren to the University of Exeter

as a thesis for the degree of Doctor of Philosophy in Biological Sciences

in June 2012

This thesis is available for Library use on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement.

I certify that all material in this thesis which is not my own work has been identified and that no material has previously been submitted and approved for the award of a degree by this or any other University.

Signature: .....

# Abstract

---

The conventional biochemical diagnosis of disease using isolated blood biomarkers must be revisited by clinicians, replacing it with a multi-biomarker, personalised profile of human health. A label-free nanoparticle array technology, Liscar, has been developed. It is capable of performing rapid, multi-biomarker assays from complex biological samples which, if employed to assay the Complement cascade of the innate immune system, has the potential for a novel systemic profile of patient health.

An assay for IgG has been developed on the Liscar platform with a detection limit of  $380 \pm 100$  ng/mL IgG in model sera. Furthermore, addition of a chaotropic agent to the complex sample is shown to improve the accuracy of the IgG assay. Competitive binding between nonspecific interfering proteins and specific target analytes (IgG) at the sensor surface is studied, and a quantitative mathematical model is developed to analyse the data, yielding evidence for the active displacement of albumin by IgG-antigen binding.

With a sensitive, accurate multi-biomarker detection platform, a systemic profile of patient health may be possible by examination of the Complement cascade. The Complement system can be activated by a variety of immunological challenges, causing large numbers of activation biomarkers to be produced quickly. Assays for three activation markers, C3d, TCC and Bb are developed, with detection limits of 0.864 ACS Units, 2.32 ng/ml and 54.7 ng/ml respectively.

Complement activation was tested in a prospective cohort study of 45 patients undergoing major abdominal surgery. Patient recovery was monitored from admission to ~60 hours postoperatively by Complement activation and consumption using C3d, TCC, Bb, C3 and C4 as biomarkers. A response profile was obtained for the entire cohort for C3 and C4 assays by normalising with respect to individual analyte levels on admission, against which individual responses are compared. 22% of patients in the study suffered postoperative complications, and 73% showed Complement activation by increased levels of C3d, as expected from the initial trauma of surgery. Expansion of the trial is needed to establish clinical significance and utility, especially in relation to the presymptomatic diagnosis of disease.

# Table of Contents

---

Table of Abbreviations .....	15
Table of Figures .....	17
Table of Tables .....	24
Chapter 1 .....	25
1.1    Biomarker Detection Techniques.....	31
1.1.1    Label-Free Biosensors .....	31
1.1.2    Chemically Labelled Biosensors .....	35
1.1.3    Other Labelled Detection Techniques.....	37
1.2    Handling Complex Biological Samples.....	37
1.2.1    Surface Chemistry Development.....	38
1.2.2    Sample Preparation Protocols.....	39
1.2.3    Kinetic Analysis of Label-free, Protein-Protein Binding Studies.....	40
1.3    Detecting Biomarkers in Clinical Samples: Monitoring Biological Systems .....	40
1.3.1    The Complement System .....	42
1.4    Assessing Biomarkers for Diagnosis .....	47
1.5    Aims and Objectives.....	50
Chapter 2.....	53
2.1    Introduction .....	53
2.1.1    Nonspecific binding.....	57
2.1.2    The Vroman Effect.....	57

2.1.3	Surface Control Proteins .....	58
2.1.4	Reducing Nonspecific Binding .....	58
2.1.5	Protein Separation .....	59
2.1.6	Protein Separation – Choatropes .....	60
2.1.7	Aims and Objectives .....	61
2.2	Method.....	61
2.2.1	Experimental .....	62
2.2.2	Chemicals .....	65
2.2.3	Sensor Surface Preparation.....	65
2.2.4	aBSA-BSA Binding Experiments.....	66
2.3	Results .....	66
2.4	Discussion.....	69
2.5	Conclusion.....	78
Chapter 3	.....	81
3.1	Introduction .....	81
3.1.1	Aims and Objectives .....	83
3.2	The Binding Models.....	84
3.3	Materials and Methods.....	86
3.3.1	Chemicals .....	88
3.3.2	Sensor Surface Preparation.....	88
3.3.3	Experiment List.....	88
3.4	Results .....	89

3.5	Discussion.....	92
3.5.1	High Affinity Binding (aBSA-BSA binding only).....	93
3.5.2	Low Affinity HSA-BSA Binding .....	97
3.5.3	Competitive Binding: HSA interference with aBSA-BSA binding.....	100
3.5.4	The Overall Global Fit – Competitive Binding Model.....	102
3.6	Conclusions .....	109
Chapter 4.....		111
4.1	Introduction .....	111
4.1.1	Previous Complement Activation Studies.....	113
4.1.2	Aims and Objectives.....	115
4.1.3	Proposed Complement Activation Study .....	115
4.1.4	Differential Complement activation monitoring.....	116
4.1.5	in vitro Complement Activation .....	118
4.2	Target Activation Fragments.....	118
4.2.1	Bb Fragment.....	119
4.2.2	C3d Fragment.....	121
4.2.3	C4d Fragment.....	123
4.2.4	The Terminal Complement Complex (TCC).....	123
4.2.5	Fragment-Specific Antibody Assays – Neoepitopes.....	124
4.3	Assay Method.....	127
4.3.1	Electrochemiluminescence Assays.....	127
4.4	Methods: Complement Activation Assay Development - TCC, Bb, C3d and C4d .....	128

4.4.1	Protocol for <i>in vitro</i> serum Complement Activation .....	128
4.4.2	Polyclonal Secondary Antibody Assays .....	129
4.4.3	SULFO-TAG® labelled monoclonal antibody assays .....	131
4.4.4	Labelling Detection Antibodies with MSD SULFO-TAG NHS Ester .....	133
4.4.5	Assay Optimisation, Calibration and Controls.....	133
4.5	Results .....	134
4.5.1	Secondary Antibody Assays.....	135
4.5.2	Tagged monoclonal assay development – TCC, Bb and C3d.....	136
4.5.3	Activated Complement Serum (ACS) Calibration– TCC and Bb Calibration .....	138
4.5.4	<i>in vitro</i> C activation assessment using Zymosan and HAIGG .....	140
4.6	Discussion.....	143
4.7	Conclusion .....	153
Chapter 5.....		155
5.1	Introduction .....	155
5.2	CPOP Trial Protocol .....	160
5.3	General Trial Results .....	163
5.4	Results and Discussion .....	168
5.4.1	Time Course Data Analysis: Nomograms .....	168
5.4.2	Complement Recovery Profiles: Stratified Nomograms .....	172
5.4.3	Complement Component Consumption .....	177
5.4.4	Secondary Complement Consumption .....	180
5.4.5	CRP vs C3 and C4 Consumption Nomograms.....	181

5.5	Conclusions .....	181
Chapter 6.....		183
6.1	Introduction .....	183
6.1.1	Complement Consumption vs Activation.....	184
6.1.2	Detection of Complement Activation Markers .....	186
6.1.3	Current Perioperative Patient Monitoring.....	187
6.1.4	Mechanisms for Complement Activation from Secondary Infections .....	190
6.1.5	Differential Complement Pathway Activation Markers .....	190
6.1.6	Aims and Objectives .....	192
6.2	Methods .....	192
6.3	Results .....	194
6.3.1	C3d Activation .....	194
6.3.2	TCC activation.....	198
6.3.3	Bb Activation .....	198
6.4	Discussion.....	199
6.4.1	Complement Fragment Clearance .....	203
6.4.2	Using the Complement System Clinically – CPOP Care .....	203
6.4.3	Case Studies .....	206
6.5	Conclusions .....	213
6.5.1	CPOP Care Conclusions .....	214
Chapter 7.....		217
7.1	Thesis Conclusions.....	218

7.2	Future Work .....	220
	Publication.....	225
	Bibliography .....	227